- -

Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC

RiuNet: Institutional repository of the Polithecnic University of Valencia

Share/Send to

Cited by

Statistics

Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC

Show simple item record

Files in this item

dc.contributor.author Jantus Lewintre, Eloisa es_ES
dc.contributor.author Sanmartin, Elena es_ES
dc.contributor.author Sirera Pérez, Rafael es_ES
dc.contributor.author Blasco, Ana es_ES
dc.contributor.author Sanchez, Jose Javier es_ES
dc.contributor.author Taron, Miguel es_ES
dc.contributor.author Rosell, Rafael es_ES
dc.contributor.author Camps, Carlos es_ES
dc.date.accessioned 2017-01-27T13:11:34Z
dc.date.available 2017-01-27T13:11:34Z
dc.date.issued 2011-11
dc.identifier.issn 0169-5002
dc.identifier.uri http://hdl.handle.net/10251/77412
dc.description.abstract Introduction: The vascular endothelial growth factor (VEGF) family of ligands and receptors (VEGFR) play an important role in tumor angiogenesis. Increased expression of angiogenic factors in tumors or in blood is associated with poor prognosis. The aim of this study was to investigate the role of VEGF-A and soluble VEGFR-2 (sVEGFR-2) as biomarkers in advanced non-small-cell lung cancer (NSCLC). Methods: We studied 432 patients with advanced NSCLC (stages IIIB-IV) treated with cisplatin and docetaxel and 89 healthy age-matched controls. Blood samples were collected before chemotherapy, and VEGF-A and sVEGFR-2 levels were determined by ELISA. Results: VEGF-A and sVEGFR-2 levels were higher in NSCLC patients than in the controls, but VEGF-A behaves as a better diagnostic biomarker. There were no significant associations between VEGF-A and sVEGFR-2 concentrations and clinical characteristics, such as ECOG-PS, gender, stage, histology, metastases, and treatment response. A patient subgroup characterized by a combination of high VEGF-A and low sVEGFR-2 levels exhibited the worst patient prognoses in terms of TTP and OS. Conclusions: VEGF-A and sVEGFR-2 levels were significantly higher in patients than in the controls. A combination of VEGF-A and sVEGFR-2 can be used as an independent prognostic biomarker in advanced NSCLC. © 2011 Elsevier Ireland Ltd. es_ES
dc.description.sponsorship This work was supported in part, by a grant [PI06/104] from Instituto de Salud Carlos III and a grant [RD06/0020/1024] from Red Tematica de Investigacion Cooperativa en Cancer (RTICC), Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation and European Regional Development Fund (ERDF) "Una manera de hacer Europa". en_EN
dc.language Inglés es_ES
dc.publisher Elsevier es_ES
dc.relation Instituto de Salud Carlos III PI06/104 es_ES
dc.relation Red Tematica de Investigacion Cooperativa en Cancer (RTICC), RD06/0020/1024 es_ES
dc.relation European Regional Development Fund (ERDF) "Una manera de hacer Europa" es_ES
dc.relation Instituto de Salud Carlos III (ISCIII) es_ES
dc.relation Spanish Ministry of Science and Innovation es_ES
dc.relation.ispartof Lung Cancer es_ES
dc.rights Reserva de todos los derechos es_ES
dc.subject Advanced NSCLC es_ES
dc.subject Biomarkers es_ES
dc.subject Prognostic es_ES
dc.subject VEGF es_ES
dc.subject VEGFR-2 es_ES
dc.subject Cisplatin es_ES
dc.subject Docetaxel es_ES
dc.subject Vasculotropin A es_ES
dc.subject Vasculotropin receptor 2 es_ES
dc.subject Adult es_ES
dc.subject Advanced cancer es_ES
dc.subject Aged es_ES
dc.subject Article es_ES
dc.subject Cancer combination chemotherapy es_ES
dc.subject Cancer diagnosis es_ES
dc.subject Enzyme linked immunosorbent assay es_ES
dc.subject Female es_ES
dc.subject Human es_ES
dc.subject Lung non small cell cancer es_ES
dc.subject Major clinical study es_ES
dc.subject Male es_ES
dc.subject Priority journal es_ES
dc.subject Prognosis es_ES
dc.subject Aged, 80 and over es_ES
dc.subject Antineoplastic Combined Chemotherapy Protocols es_ES
dc.subject Carcinoma, Non-Small-Cell Lung es_ES
dc.subject Disease Progression es_ES
dc.subject Humans es_ES
dc.subject Lung Neoplasms es_ES
dc.subject Middle Aged es_ES
dc.subject Neoplasm Staging es_ES
dc.subject Taxoids es_ES
dc.subject Tumor Markers, Biological es_ES
dc.subject Vascular Endothelial Growth Factor A es_ES
dc.subject Vascular Endothelial Growth Factor Receptor-2 es_ES
dc.subject.classification MICROBIOLOGIA es_ES
dc.title Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC es_ES
dc.type Artículo es_ES
dc.identifier.doi 10.1016/j.lungcan.2011.02.016
dc.rights.accessRights Cerrado es_ES
dc.contributor.affiliation Universitat Politècnica de València. Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural - Escola Tècnica Superior d'Enginyeria Agronòmica i del Medi Natural es_ES
dc.description.bibliographicCitation Jantus Lewintre, E.; Sanmartin, E.; Sirera Pérez, R.; Blasco, A.; Sanchez, JJ.; Taron, M.; Rosell, R.... (2011). Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer. 74(2):326-331. doi:10.1016/j.lungcan.2011.02.016 es_ES
dc.description.accrualMethod Senia es_ES
dc.relation.publisherversion https://dx.doi.org/10.1016/j.lungcan.2011.02.016 es_ES
dc.description.upvformatpinicio 326 es_ES
dc.description.upvformatpfin 331 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion es_ES
dc.description.volume 74 es_ES
dc.description.issue 2 es_ES
dc.relation.senia 221012 es_ES


This item appears in the following Collection(s)

Show simple item record